Dow DOW
Basic Materials · Chemicals · Synthos Deep Dive · 2026-07-03
The Overview
Dow makes the basic plastics and chemicals that go into packaging, paint, foam, and countless everyday products. It sells commodities: when the world economy is humming, prices are high and Dow prints money; when demand is soft and there's too much supply (which is now), prices fall and Dow loses money. Right now it's the bad part of that cycle — the company lost billions last year, is spending more cash than it brings in, and cut its dividend to protect itself.
The stock is cheap — down about 60% from its peak — which is exactly what a beaten-down cyclical looks like near a bottom. But cheap can stay cheap, or get cheaper, if the industry slump drags on. Our verdict is Watch: not a buy today for most people, but worth keeping an eye on for a turnaround.
Here's what our three scores mean in everyday terms:
- Downside Risk 7/10 (high). The company is losing money, carries a lot of debt relative to what it earns right now, and already trimmed its dividend once — another leg down is a real possibility.
- Growth Quality 2/10 (poor). This isn't a steady grower; it's a boom-and-bust commodity business with thin, swingy profits and no special pricing power.
- Exponential Potential 2/10 (very low). It's a mature, slow-moving giant. If it recovers, that's the cycle turning — not a rocket ship.
The one big worry: if the chemical downturn keeps going, Dow keeps burning cash, and it may have to cut the dividend again and the stock could fall further before it recovers.
Putting a number on it: our fair-value estimate is $29 against a current price of $30.51 — consistent with our call to stay away or wait for a better setup.
Our summary metrics
Loss-making trough, net-debt/EBITDA 18.5×, negative FCF, dividend already halved — cyclical + secular oversupply. Low beta only partial offset.
Negative TTM margins, negative ROIC/ROE, no commodity-chemical pricing power; any 2026-27 "growth" is cyclical mean-reversion, not durable.
Mature commodity chemical in a down-cycle; recovery is reversion, not acceleration. No exponential engine.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature commodity chemical in a down-cycle; recovery is reversion, not acceleration. No exponential engine.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $37.33 (high $46 / low $28; 0 Strong-Buy · 11 Buy · 19 Hold · 5 Sell = Hold) — context, not our anchor |
| Valuation | Loss-making on trailing EPS (P/E n/m) · EV/EBITDA 42× trailing on depressed EBITDA · EV/S 0.9× · P/B 1.3× |
| Technicals | Downtrend — $27.71, −34% off 52-wk high, below 50/200-DMA, RSI 11.8 (deeply oversold), −0.4% 12-mo (SPY +21%) |
| Conviction | Low — 0 DOW-specific expert voices; the 4 KB claims are Brent Johnson macro/technical calls, not name-level |
| Position sizing | Not a core holding; if owned at all, a small (~1–2%) contrarian/cyclical satellite for turnaround-minded investors only |
What the experts actually said 10 traceable claims on DOW · showing the highest-conviction voices
“Meltup underway; indexes up 30-40% within a few months. Targets: Dow 70,000, S&P 10,000, NASDAQ 36,000, Russell 4,000 — 'couldn't be more bullish short-term'.”
“In a sovereign-debt/currency crisis US equities go higher, not lower — capital flows into dollar-denominated assets under the milkshake framework.”
“US producers back-integrated to cheap domestic natural gas but selling globally-priced products — CF Industries, Dow, Huntsman — will be huge beneficiaries and 'printing cash' as European supersites go offline.”
“Bullish stocks all year and highs are not in; market keeps going higher because everyone came in too short and fundamental macro bears haven't capitulated yet.”
“Indices sit at all-time highs above moving averages with healthy relative strength; no specific near-term catalyst seen to derail the uptrend.”
“Over 20% of stocks show DeMark 13 sell counts alongside overbought RSI/stochastics — indices and megacaps are set up for a near-term pullback.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $30.51, 2% above the 50-day average ($30), 2% below the 200-day average ($31) — a mixed trend. 27% below the 52-week high of $42, 48% above the 52-week low of $21.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $30.51 is currently inside the band (band $29–$33).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 48.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.09, negative momentum.
Relative performance vs S&P 500 & its sector (XLB (sector)), set to 100 a year ago
Solid = DOW · dashed = S&P 500 · dotted = XLB (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Dow Inc. (NYSE: DOW) is one of the world's largest materials-science / commodity-chemical companies, spun out of DowDuPont in 2019 and headquartered in Midland, Michigan. It makes foundational chemicals and polymers — ethylene, propylene, polyethylene, polyurethanes, silicones, coatings — sold into packaging, infrastructure, mobility, and consumer end-markets. This is a price-taking, capital-intensive, deeply cyclical business: profitability tracks the global spread between feedstock costs and product prices, which is currently compressed by soft demand and industry oversupply. Fiscal year ends December 31. CEO: James R. Fitterling.
Revenue mix (FY2025, from filings):
- By segment: Packaging & Specialty Plastics $19.97B (50%) · Industrial Intermediates & Infrastructure $11.16B (28%) · Performance Materials & Coatings $8.13B (20%). The plastics segment is the swing factor — polyethylene/olefins pricing drives the whole P&L.
- By geography: U.S. & Canada $15.81B (40%) · Europe/Middle East/Africa/India $12.59B (31%) · Asia Pacific $7.22B (18%) · Latin America $4.35B (11%). Genuinely global, which spreads the demand base but also exposes Dow to European feedstock disadvantages and Middle East conflict disruption (both cited in management's Q1'26 release).
The structural backdrop: revenue has fallen every year since the 2022 peak ($56.9B → $44.6B → $43.0B → $40.0B FY25), as the post-COVID chemical super-cycle unwound into oversupply. Management's response is a self-help program ("Transform to Outperform") — cost cuts, an idled European cracker, and a shuttered U.S. Gulf Coast propylene-oxide unit — plus a halved dividend to defend the balance sheet.
2. The expert thesis (traceable)
There is no DOW-specific expert coverage in the Synthos knowledge base. total_claims is 4, but all four are Brent Johnson macro/technical calls about the broad U.S. equity market and indices — not about Dow the company:
brent_johnson-lXidpA90QK8:e98d7f6f6e(bullish, conviction 60, 2026-01-11): "Indices sit at all-time highs above moving averages with healthy relative strength; no specific near-term catalyst seen to derail the uptrend." — a market-breadth observation, not a Dow thesis.brent_johnson-75Xx_DaFZVU:9a2d7c950f(bearish, conviction 68, 2025-06-08): "Over 20% of stocks show DeMark 13 sell counts alongside overbought RSI/stochastics — indices and megacaps set up for a near-term pullback." — again index-level.
Honest read: these claims carry zero name-level signal for Dow and net to no directional conviction on the stock. They are logged here only for full traceability; we do not lean on them. This verdict is therefore fundamentals- and quant-driven, not conviction-driven. kb_breadth = 0, kb_net_conviction = 0. When a name has no expert panel, Synthos says so plainly rather than manufacturing a thesis.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics:
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 7 · High | FY25 net loss −$2.6B, negative FCF (−$1.45B), net-debt/EBITDA 18.5× on trough EBITDA, dividend already halved, commodity cyclicality + secular oversupply. Beta 0.405 and a −60% drawdown (a lot already priced in) are the only offsets. |
| Growth Quality | 2 · Poor | Negative TTM margins (net −7.0%, operating −2.3%), negative ROIC/ROE (−1.8% / −16.7%), no commodity pricing power. Any 2026-27 "growth" is cyclical mean-reversion off a trough, not durable compounding. |
| Exponential Potential | 2 · Low | Mature commodity chemical in a down-cycle; the second derivative is a cyclical bounce, not structural acceleration. No exponential engine, no room-to-run story. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). Because Dow is a cyclical, the honest valuation lens is EV/EBITDA on mid-cycle earnings, not trailing P/E (earnings are negative). Net debt ~$15.8B; ~721M shares. We deliberately do not attach probabilities.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Chemical cycle inflects in 2026-27; volumes/spreads recover; self-help delivers. EBITDA normalizes to ~$6.5B, market pays a mid-cycle ~8× EV/EBITDA → EV ~$52B − $16B net debt ≈ $36B equity. | ~$46 (+66%) |
| Base (our anchor) | Partial, gradual recovery toward consensus mid-cycle EBITDA ~$5.5B at a ~7× multiple → EV ~$38.5B − $15.8B ≈ $22.7B equity. Roughly matches the Street low. | ~$29 (+5%) |
| Bear | Down-cycle persists; EBITDA stuck near ~$3.5B, multiple de-rates to ~6× → EV ~$21B − $17B net debt ≈ $4–5B equity; a second dividend cut compounds the de-rating. | ~$14 (−49%) |
Synthos fair value = the base case, ~$29 (+5%), with the full $14–$46 span as the honest range. Note the enormous asymmetry driven by leverage: because net debt (~$16B) is large relative to equity value (~$20B), small swings in mid-cycle EBITDA and the multiple produce huge swings in the equity — that is the signature of a levered cyclical near a trough, and the reason this is a Watch, not a Buy. Our base sits below the Street's $37.33 consensus: we are not willing to underwrite a full cycle recovery at today's evidence. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers). Dow is neither — it is a mature, mean-reverting commodity cyclical:
- Forward growth is a rebound, not a trend: consensus has revenue recovering from $40.0B (FY25) toward ~$45.0B (FY26E) and EPS swinging from −$3.69 (FY25) to ~$3.07 (FY26E). Caveat: those estimates look stale/optimistic against the current run-rate — Q1'26 revenue annualizes to only ~$39B and Q1 posted a net loss, so treat the FY26 recovery figures as a hopeful analyst mid-point, not a commitment.
- Acceleration (2nd derivative): the only "acceleration" is the base effect of climbing off a loss-making trough. Beyond a cyclical bounce there is no structural growth engine — volumes are flat-to-down, European assets are being idled, and the product set is commoditized.
- Room to run: at ~$20B market cap the company isn't capped by size, but its addressable markets (bulk plastics, intermediates) are mature and oversupplied — the constraint is margin, not TAM.
- Reinvestment runway: negative. FCF is −$1.45B; capex ($2.48B) exceeds operating cash flow ($1.03B). Dow is currently shrinking its asset base (idling crackers), the opposite of a reinvestment-driven compounder.
Exponential Potential: Low (2/10). Own Dow — if at all — for a cyclical/deep-value recovery, explicitly not for growth or compounding.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $39.97B, −7% (FY24 $42.96B; down every year from the $56.9B FY22 peak). Q1'26 $9.79B, −6% YoY.
- Profitability collapsed: FY25 net loss −$2.62B (EPS −$3.69) vs FY24 net income +$1.10B (EPS +$1.57). EBITDA fell to $1.19B FY25 (from $5.25B FY24). Q4'25 was especially ugly (EBITDA −$0.62B); Q1'26 net loss −$445M, operating EPS −$0.14.
- Margins (TTM): gross 6.2%, operating −2.3%, net −7.0% — thin and negative, the hallmark of a commodity trough.
- Returns on capital: ROIC −1.8%, ROE −16.7%, ROA −4.6% — destroying economic value at this point in the cycle.
- Cash flow: operating CF $1.03B FY25, capex −$2.48B → free cash flow −$1.45B. FCF was already only −$0.15B in FY24 and +$2.7B in FY23 — the trend is sharply negative. This is the single most important tell — until FCF turns positive, the recovery is unproven.
- Balance sheet: total debt $19.6B, net debt $15.8B; net-debt/EBITDA 18.5× on trough EBITDA (would be a more manageable ~3× on mid-cycle $5.5B EBITDA — the whole bull case rests on that normalization). Current ratio 1.85×; cash $3.8B. Investment-grade but stretched here.
- Dividend: trailing dividend $1.40/share (~5% yield) — already cut roughly in half from the historical ~$2.80 rate. FY25 dividends paid $1.49B against negative FCF, funded by debt/asset sales — not sustainable if the trough persists.
6. Valuation — cheap, or a value trap?
On trailing earnings Dow is loss-making (P/E not meaningful; EV/EBITDA 42× on depressed TTM EBITDA — a misleadingly high number because the denominator is trough). The only sensible cyclical lenses:
- EV/Sales 0.9× and P/B 1.3× — both point to a genuinely cheap asset base, consistent with a cyclical bottom.
- Mid-cycle EV/EBITDA: at consensus normalized EBITDA ~$5.5B and today's ~$35.5B EV, the forward mid-cycle multiple is ~6.5× — reasonable for a commodity chemical, cheap if the cycle turns.
- Forward P/E on the (optimistic) FY26E EPS ~$3.07 is ~9× — but that estimate is the crux of the debate; if the recovery slips, the "cheap" multiple evaporates.
Street targets (context): consensus $37.33 (high $46, low $28), rating Hold (0 Strong-Buy, 11 Buy, 19 Hold, 5 Sell); FMP letter rating C+ (overall score 2/5, weak on ROE/ROA/debt/P-E). Our base FV of $29 sits deliberately below consensus and near the Street low — we credit the asset value but refuse to underwrite a full recovery on faith. Not a value buy yet; a value watch.
7. Technicals (from the tech block)
- Trend: down. $27.71 sits below both the 50-DMA ($35.12) and 200-DMA ($29.84), with the 50 below the 200 (death-cross posture). MACD −2.20 (negative).
- Location: −33.8% off the 52-week high ($41.87), +34% off the 52-week low ($20.65); max drawdown from peak −60.9% — a badly damaged chart.
- Momentum: RSI(14) 11.8 — deeply oversold (<30 is oversold; sub-15 is extreme). This is a two-edged read: it flags capitulation (contrarian bounce potential) and confirms an active downtrend. Not a signal to chase in either direction.
- Relative strength (the tell): DOW −0.4% 12-mo vs SPY +20.6% and QQQ +30.3%; −31.9% 3-mo vs SPY +13.7%. Persistent, severe underperformance of both the market and tech.
- Read: technicals confirm the fundamental weakness. The extreme oversold reading is the only bull tell — a mean-reversion bounce is possible, but there is no trend support to lean on. Wait for the chart to stabilize (reclaim the 50-DMA, MACD cross positive) before treating a bottom as in.
8. Moat & competitive position
Dow's "moat" is scale and integration, not pricing power — it is a low-cost, vertically integrated producer with an advantaged Americas feedstock (shale-gas ethane) position and global logistics. In a commodity business that lowers the cost floor but does not confer durable margins: when the industry is oversupplied, even the low-cost producer loses money, as FY25 proved. Structural headwinds are real — European assets are cost-disadvantaged (Dow idled an EMEAI cracker in mid-2025), Middle East conflict is disrupting the Industrial Intermediates segment, and global polyethylene/olefins capacity additions keep spreads compressed.
Peer set (market cap): LyondellBasell $17.2B (closest commodity-chemical comp), DuPont $18.9B, PPG $27.9B, IFF $21.4B, Albemarle $16.0B, SQM $20.8B, RPM $14.2B, Reliance Steel $19.0B, CEMEX $17.8B, POSCO $15.8B. Dow is the largest by revenue and among the most cyclical; the specialty peers (PPG, RPM, IFF) command richer multiples precisely because they are less commoditized.
9. Management, capital allocation & guidance
- Capital allocation: playing defense — a ~50% dividend cut, cost reductions ("Transform to Outperform"), idled/shuttered high-cost assets, and receipt of a NOVA Chemicals litigation payment to shore up liquidity. Buybacks have stopped (net stock issuance was slightly positive in FY25). Appropriate for the cycle, but confirms the balance sheet is under pressure.
- Insider activity: the recent Form 4s are all routine equity awards to directors and the CEO (grants, price $0), dated Feb–Apr 2026 — no open-market buying signal and no alarming discretionary selling in the sampled window.
- Management's own guidance (half-weighted — they talk their own book): The Q1'26 earnings release (SEC 8-K, filed 2026-04-23) is a genuine results release. Management's forward tone: CEO Jim Fitterling says "the margin backdrop began to positively inflect in March following global supply constraints," claims "rapid positive momentum from our announced pricing actions in every business and every region," and frames "Transform to Outperform" as positioning the company for "expanded margins and higher shareholder returns across the cycle." Honest weighting: this is management's self-interested framing of a quarter that still posted a $445M net loss and a −$0.14 operating EPS; the "positive inflection" is a hopeful qualitative claim, not yet visible in the numbers. Treat as a data point, not a thesis. Dow did not provide specific quantitative full-year EPS/EBITDA guidance in the release.
10. Catalysts & what to watch
- Next earnings: 2026-07-23 (Q2'26; Street EPS $1.23, revenue ~$12.0B — both look stale/high vs the current run-rate; watch for downward revision or a miss). The key lines: polyethylene/olefins pricing and volumes, operating EBITDA direction, and any FCF improvement.
- Free-cash-flow inflection: the single most important tell. FCF turning positive would validate the self-help program and the dividend.
- Chemical cycle: industry polyethylene spreads, capacity additions/rationalization, and Chinese demand — the macro that ultimately decides the P&L.
- Dividend durability: whether the (already-cut) $1.40 payout holds; a second cut would be a major negative catalyst.
- Cost program & asset actions: further European/high-cost idling and "Transform to Outperform" savings realization.
Thesis tripwires (what would change the call — to more bullish): two consecutive quarters of positive FCF; operating EBITDA back above ~$4B annualized; polyethylene spreads inflecting. To more bearish: a second dividend cut; net-debt/EBITDA staying in double digits into 2027; continued negative FCF.
11. Key risks
- Prolonged down-cycle (structural + cyclical): commodity spreads could stay compressed for years amid global oversupply; Dow loses money and burns cash at the trough.
- Leverage on trough earnings: net-debt/EBITDA 18.5× today; if EBITDA doesn't normalize, the balance sheet tightens and a second dividend cut / rating pressure follows.
- Negative free cash flow: capex exceeds operating cash flow; the dividend is currently debt-funded.
- Geographic/geopolitical: European feedstock disadvantage (cracker idled) and Middle East conflict disrupting Industrial Intermediates.
- Value trap: "cheap on assets" can persist or worsen; there is no expert conviction and no growth catalyst to force a re-rating — only the cycle.
- No expert coverage: the Synthos KB has zero name-level signal on Dow — this call rests entirely on quant/fundamentals, which is itself a (disclosed) limitation.
12. Verdict, position sizing & monitoring
Watch. Dow is a genuinely cheap, blue-chip commodity cyclical in a deep down-cycle — FY25 net loss −$2.6B, negative FCF, stretched leverage on trough EBITDA, a dividend already halved, and a badly damaged chart (RSI 11.8, −60% max drawdown). The deep-value / cycle-recovery optionality is real and the asset base is cheap (EV/Sales 0.9×, P/B 1.3×), but there is no expert conviction, no growth engine, and no evidence yet that the cycle has turned. Buying today is a macro bet on the chemical cycle inflecting — not a bet on a moat or a compounder.
- Sizing: not a core holding. For turnaround-minded investors only, a small (~1–2%) contrarian/cyclical satellite, scaled in on evidence (FCF turning positive, EBITDA recovering), not on the oversold bounce alone.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. Upgrade to Buy — Tactical only if FCF inflects positive and mid-cycle EBITDA visibility improves.
- Single biggest risk: a prolonged down-cycle that forces a second dividend cut and further de-rating before the recovery arrives.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $27.71.
Provenance & disclosures
- Traceability: 4 KB claims, breadth 0 DOW-specific voices — all four are Brent Johnson macro/technical calls (
brent_johnson-lXidpA90QK8:e98d7f6f6e,brent_johnson-75Xx_DaFZVU:9a2d7c950f), cited only for completeness and not relied upon. This is a fundamentals-/quant-driven verdict. Fabricated conviction is structurally impossible (claim-ID reconciliation). - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · the only KB claims date to 2026-01-11 and earlier. Forward figures are analyst consensus (FMP), labeled as estimates; several FY26 consensus figures appear stale/optimistic vs the current run-rate and are flagged as such.
- Management caveat: management's Q1'26 8-K commentary is management's own book, half-weighted by design; no specific quantitative full-year guidance was issued.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").